Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotech firm, will present an overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 12:45 p.m. PT. The presentation will highlight Bolt's innovative immuno-oncology therapeutics that utilize Boltbody™ to target tumors. Key products include BDC-1001, a HER2-targeting agent in a Phase 1/2 trial, and others targeting CEA and Dectin-2. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event.

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022, at 12:45 p.m. PT (3:45 p.m. ET).

A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt Bio’s proprietary Boltbody™ Immune-stimulating Antibody Conjugates (ISACs) are designed to target tumor cells for elimination by the immune system. BDC-1001 is a HER2-targeting Boltbody ISAC in an ongoing Phase 1/2 clinical trial enrolling patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and BDC-3042, an agonist antibody targeting Dectin-2. BDC-3042 is the first candidate to be advanced from the company’s myeloid modulator platform. In addition, Bolt Bio is developing new immuno-oncology Boltbody ISACs through strategic collaborations with leading biopharmaceutical companies.

Investor Relations and Media Contacts:
Karen L. Bergman
Vice President, Communications and Investor Relations
Bolt Biotherapeutics, Inc.
650-665-9295
kbergman@boltbio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

Maggie Beller or David Schull
Russo Partners, LLC
646-942-5631
maggie.beller@russopartnersllc.com
david.schull@russopartnersllc.com

FAQ

When is Bolt Biotherapeutics presenting at the Needham Healthcare Conference?

Bolt Biotherapeutics will present on April 14, 2022, at 12:45 p.m. PT.

Where can I watch the Bolt Biotherapeutics conference presentation?

The presentation can be viewed live on Bolt's website, with archived replays available for 30 days.

What is Bolt Biotherapeutics known for?

Bolt Biotherapeutics specializes in immuno-oncology therapeutics that target tumor cells using their Boltbody™ platform.

What clinical trials is Bolt Biotherapeutics currently conducting?

Bolt is conducting a Phase 1/2 trial for BDC-1001, targeting HER2-expressing solid tumors.

What are the main products developed by Bolt Biotherapeutics?

Key products include BDC-1001, BDC-2034 targeting CEA, and BDC-3042, an agonist antibody for Dectin-2.